Actinium Pharmaceuticals ... (ATNM)
1.22
0.05 (4.27%)
At close: Feb 20, 2025, 3:59 PM
1.18
-3.28%
After-hours: Feb 20, 2025, 04:21 PM EST
undefined% (undefined)
| Bid | 1.18 |
| Market Cap | 38.06M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.39 |
| PE Ratio (ttm) | -0.88 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 1.24 |
| Volume | 120,837 |
| Avg. Volume (20D) | 277,830 |
| Open | 1.17 |
| Previous Close | 1.17 |
| Day's Range | 1.15 - 1.23 |
| 52-Week Range | 1.07 - 10.24 |
| Beta | undefined |
About ATNM
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19...
Industry Biotechnology
Sector Healthcare
IPO Date Dec 27, 2012
Employees 37
Stock Exchange AMEX
Ticker Symbol ATNM
Website https://www.actiniumpharma.com
Analyst Forecast
According to 4 analyst ratings, the average rating for ATNM stock is "Buy." The 12-month stock price forecast is $5, which is an increase of 309.84% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
6 months ago
+15.73%
Actinium Pharmaceuticals shares are trading higher...
Unlock content with
Pro Subscription
6 months ago
-59.81%
Actinium shares are trading lower after the FDA determined that its Phase 3 SIERRA trial is not adequate to support a BLA filing for Iomab-B.
